Announcement of The Consolidated Financial Report for The 1st Quarter of 2023
2023.5.5
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2022/05/05 | Time of announcement | 17:26:11 |
| Subject | Announcement of The Consolidated Financial Report for The 1st Quarter of 2023 | ||||
| Date of events | 2022/05/05 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2023/05/05 2.Date of the audit committee approved:2023/05/05 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2023/01/01~2023/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):1,166,332 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):711,974 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):245,399 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):293,342 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):234,541 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):238,680 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.96 11.Total assets end of the period (thousand NTD):9,565,737 12.Total liabilities end of the period (thousand NTD):3,941,672 13.Equity attributable to owners of parent end of the period (thousand NTD):5,048,874 14.Any other matters that need to be specified:None |
||||